Jennifer L. Ennis, MD

Because of biological variability in lipid metabolism and the effects of lipid-lowering therapies, the cholesterol content carried in LDL particles varies greatly among patients and in the same patient over time. When measures of LDL-P quantity differ from LDL-C in terms of percentiles, apo B or NMR-measured LDL-P consistently demonstrate a significantly stronger association with CHD outcomes than LDL-C in prospective epidemiologic studies and better predict on-treatment residual risk in clinical trials.

Because of biological variability in lipid metabolism and the effects of lipid-lowering therapies, the cholesterol content carried in LDL particles varies greatly among patients and in the same patient over time. When measures of LDL-P quantity differ from LDL-C in terms of percentiles, apo B or NMR-measured LDL-P consistently demonstrate a significantly stronger association with CHD outcomes than LDL-C in prospective epidemiologic studies and better predict on-treatment residual risk in clinical trials.

Because of biological variability in lipid metabolism and the effects of lipid-lowering therapies, the cholesterol content carried in LDL particles varies greatly among patients and in the same patient over time. When measures of LDL-P quantity differ from LDL-C in terms of percentiles, apo B or NMR-measured LDL-P consistently demonstrate a significantly stronger association with CHD outcomes than LDL-C in prospective epidemiologic studies and better predict on-treatment residual risk in clinical trials.